Phathom Pharmaceuticals Competitors and Similar CompaniesClear all
Phathom Pharmaceuticals's competitors and similar companies include Restech and Immatics.
 Phathom Pharmaceuticals Phathom Pharmaceuticals is a biopharmaceutical company focused on treating gastrointestinal diseases and disorders. |  Restech Restech is a digestive health solutions company that offers minimally invasive tools to multiple specialties in order to diagnose and manage reflux. |  Immatics Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. | |
Founding Date | Founding Date 2018 | Founding Date 2003 | Founding Date N/A |
Type | Type Public | Type Private | Type Public |
Tags | |||
Locations | Locations Buffalo Grove, US HQ Florham Park, US Menlo Park, US | Locations Houston, US HQ | Locations Tübingen, DE HQ Frankfurt Am Main, DE München, DE Houston, US |
Employees | Employees 1633% increase | Employees 783% decrease | Employees 29723% increase |
Valuation ($) | Valuation ($) 1.2 b | Valuation ($) N/A | Valuation ($) 1.1 b |
Financial | |||
Revenue (est.) | Revenue (est.) $175.1m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) €48.3m (FY, 2025) |
Cost of goods | Cost of goods $22.6m (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $152.5m (FY, 2025) | Gross profit N/A | Gross profit €53m (FY, 2025) |
Net income | Net income ($221.2m) (FY, 2025) | Net income N/A | Net income (€196.4m) (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 140m | Total funding raised N/A | Total funding raised $ 267.3m |
For sources of this data, please see the company profile
View Company Profiles
Restech
HQ
Houston, US
Employees
78↓ 3% decrease
Restech is a digestive health solutions company that offers minimally invasive tools to multiple specialties in order to diagnose and manage reflux.
View companyImmatics
HQ
Tübingen, DE
Employees
297↑ 23% increase
Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer.
View company